Lupin settles patent dispute with Astellas Pharma to keep selling bladder drug in US
Lupin will pay ninety million dollars to Astellas Pharma to settle a patent dispute over its generic bladder drug. This deal allows sales to continue in the US.
Insights:
Lupin Limited , headquartered in India 
IN, has officially settled a patent infringement dispute with Japan 
JP based Astellas Pharma Inc. regarding the bladder drug Mirabegron (Myrbetriq). The settlement, finalized on February 10, 2026, resolves all pending litigation between the parties and allows Lupin to continue marketing the medication in the United States 
US.
IN, has officially settled a patent infringement dispute with Japan JP based Astellas Pharma Inc. regarding the bladder drug Mirabegron (Myrbetriq). The settlement, finalized on February 10, 2026, resolves all pending litigation between the parties and allows Lupin to continue marketing the medication in the United States US.
